Overview

A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes (SURPASS-CN-MONO)

Status:
Active, not recruiting
Trial end date:
2024-09-24
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to investigate the efficacy and safety of Tirzepatide monotherapy in Chinese participants with Type 2 Diabetes.
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Tirzepatide